← Leaderboards
Thomas Russell Pisanic II
Johns Hopkins University
$1,520,495
Attributed
$4,103,955
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $867.7K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,103,955 · 3
By mechanism
R01$2,125,930 · 1
R33$1,249,508 · 1
R21$728,517 · 1
Top collaborators
- Tza-Huei Jeff Wang8 shared
- Ie-Ming Shih5 shared
- Tian-Li Wang5 shared
- Hariharan Easwaran3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Tza-Huei Jeff Wang$29,391,444
- Cornelia L Trimble$7,319,162
- Amanda Nickles Fader$1,935,907
- Leah Helane Rubin$12,441,193
- Charles W. Flexner$41,000,447
Others in their field
Other Emerging Leaders on “Sampling”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,167,581
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Scott Topper · Broad Institute, Inc.$77,958,806
- Paul F Gallagher · Woods Hole Oceanographic Institution$63,916,876
- Leonard Freedman · Leidos Biomedical Research, Inc.$60,323,945
- Dale Sandler · Social And Scientific Systems, Inc.$59,740,435
Research focus
SamplingMethylationDna MethylationTechnologyMalignant NeoplasmsTumorTissuesMicrofluidicsMeltingComplexMalignant Neoplasm Of OvaryBiological MarkersMicrofluidic MicrochipsCohortNeoplastic CellMethylation BiomarkerPerformanceDetectionCost EffectiveEarly Detection BiomarkersFluorescenceDigitalCancer TypeCost
Grant awards (11)
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$417,626
R01 · FY2025 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$406,959
R01 · FY2024 · CA
A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies$402,275
R33 · FY2024 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$423,593
R01 · FY2023 · CA
A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies$413,468
R33 · FY2023 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$433,937
R01 · FY2022 · CA
A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies$433,765
R33 · FY2022 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$443,815
R01 · FY2021 · CA
High-efficiency microfluidic-assisted single-cell DNA methylome sequencing$319,767
R21 · FY2019 · CA
High-efficiency microfluidic-assisted single-cell DNA methylome sequencing$245,250
R21 · FY2018 · CA
High-efficiency microfluidic-assisted single-cell DNA methylome sequencing$163,500
R21 · FY2017 · CA